Keyword: Samsung BioLogics

Former China FDA chief resigns over vaccine scandal; Astellas buys gene therapy specialist Quethera; FDA found problems at valsartan maker Huahai.

Lenvima's quarterly sales grow to $106 million; China makes 48-drug list for streamlined review; Samsung commits further investment in biologics.

Samsung BioLogics is slated to get a piece of the $22 billion investment Samsung says it will invest in growth businesses.

Eisai and Biogen's recent Alzheimer's data spark debate; Beijing works to contain a vaccine scandal; BMS and Tsinghua University pen drug discovery pact.

Korean CDMO Samsung BioLogics has won FDA approval for its first finished product at the second of three plants built in rapid succession.  

Biogen and Eisai's anti-amyloid candidate shows promise; Otsuka signs two M&A deals; Samsung BioLogics faces criminal probe over Biogen JV agreement.

South Korean regulators have ruled on a case of alleged accounting violations at Samsung BioLogics and sent their findings to prosecutors.

Sanofi launches a big data-focused global R&D hub in China; Takeda looks to sell its old HQ for $542 million; I-Mab gets $220 million in series C.

Biogen will pay about $700 million to boost its stake in Samsung Bioepis to 49.9%. It currently owns 5.4% of the biosimilars joint venture.

China conditionally approves Merck's Gardasil 9; Biogen looks to up its stake in Samsung Bioepis; WuXi plots a series of major expansions; and more.